<DOC>
	<DOCNO>NCT02309918</DOCNO>
	<brief_summary>This open-label , single arm , multicenter , pilot-study compare efficacy safety LDV/SOF fix dose combination ( FDC ) subject acute genotype 1 HCV infection . A total 20 subject assign receive LDV/SOF FDC tablet ( LDV 90 mg/SOF 400 mg/ ) daily 6 weeks.Patients follow 24 week .</brief_summary>
	<brief_title>HepNet Acute HCV IV - LDV/SOF FDC Acute Genotype 1 Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>1 . Willing able provide write informed consent 2 . Male female , age ≥ 18 year 3 . HCV RNA ≥ 103 IU/mL Screening 4 . Confirmation acute genotype 1 HCV infection document either : document seroconversion HCV antibody positivity within 4 month precede screen know suspected exposure HCV within 4 month precede screen 10 time elevated serum ALT Level screen 4 week precede screen without evidence confound liver disorder 5 . If patient visit physician due symptom acute HCV , great 12 week interval may elapse time visit screen 6 . Noncirrhotic . Absence cirrhosis determine base clinical parameter ultrasound 7 . Body mass index ( BMI ) ≥ 18 kg/m2 8 . Screening ECG without clinically significant abnormality 9 . Subjects must follow laboratory parameter screen : 1 . Hemoglobin ≥ 10 g/dL 2 . Platelets ≥ 90,000/µL 3 . INR ≤1.5 x ULN unless subject know hemophilia stable anticoagulant regimen affect INR 4 . Albumin ≥ 3 g/dL 5 . HbA1c ≤ 10 % 6 . Creatinine clearance ( CLcr ) ≥ 60 mL/min , calculate Cockcroft Gault equation 10 . Subject treated investigational drug device within 42 day Screening visit 11 . A negative serum pregnancy test require female subject ( unless surgically sterile woman ≥ 54 year age cessation 24 ≥ month previously occur menses ) . Complete abstinence intercourse . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) permit . Or Consistent correct use 1 follow method birth control list , addition male partner correctly use condom , date Screening 30 day last dose study drug : intrauterine device ( IUD ) failure rate &lt; 1 % per year female barrier method : cervical cap diaphragm spermicidal agent tubal sterilization vasectomy male partner hormonecontaining contraceptive : implant levonorgestrel injectable progesterone oral contraceptive ( either combine progesterone ) contraceptive vaginal ring transdermal contraceptive patch 12 . Male subject must agree refrain sperm donation day screen least 90 day last dose study drug . 13 . Subject must generally good health determine Investigator . 14 . Subject must able comply dose instruction study drug administration able complete study schedule assessment . 1 . Clinicallysignificant illness ( HCV ) major medical disorder , opinion investigator , may interfere subject treatment , assessment compliance protocol ; subject currently evaluation potentially clinicallysignificant illness ( HCV ) also exclude . 2 . Gastrointestinal disorder post operative condition could interfere absorption study drug ( example , gastric bypass severe ulcerative colitis ) . 3 . Difficulty blood collection and/or poor venous access purpose phlebotomy . 4 . Clinical hepatic decompensation ( i.e. , clinical ascites , encephalopathy variceal hemorrhage ) . 5 . Solid organ transplantation . 6 . Significant pulmonary disease significant cardiac disease . 7 . Psychiatric hospitalization , suicide attempt , and/or period disability result psychiatric illness within last 2 year . Subjects psychiatric illness wellcontrolled stable treatment regimen least 12 month prior screen require medication last 12 month may include . 8 . Malignancy within 5 year prior screen , exception specific cancer entirely cure surgical resection ( basal cell skin cancer , etc ) . Subjects evaluation possible malignancy eligible . 9 . Significant drug allergy ( anaphylaxis hepatotoxicity ) . 10 . Any prior treatment HCV infection include prior exposure inhibitor NS5B NS5A . 11 . Pregnant nursing female male pregnant female partner 12 . Chronic liver disease nonHCV etiology ( e.g. , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , Wilson 's disease , α1 antitrypsin deficiency , cholangitis ) 13 . Infection hepatitis B virus ( HBV ; define HBsAgpositive ) human immunodeficiency virus ( HIV ) 14 . Chronic use systemically administer immunosuppressive agent ( e.g. , prednisone equivalent &gt; 10 mg/day ) 15 . Clinicallyrelevant drug alcohol abuse within 12 month screen include uncontrolled drug use within 6 month screen . A positive drug screen exclude subject unless explain prescribed medication ; diagnosis prescription must approve investigator . Uncontrolled user intravenous drug permit enroll study . 16 . Donation loss 400 ml blood within 2 month prior Baseline/Day 1 17 . Use prohibit concomitant medication within 21 day Baseline/Day 1 visit , washout period apply proton pump inhibitor , take 7 day Day 1 . 18 . Known hypersensitivity LDV , SOF formulation excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>acute HCV Genotype 1 Infection</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>LDV/SOF FDC</keyword>
</DOC>